CL2015002442A1 - Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd - Google Patents

Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd

Info

Publication number
CL2015002442A1
CL2015002442A1 CL2015002442A CL2015002442A CL2015002442A1 CL 2015002442 A1 CL2015002442 A1 CL 2015002442A1 CL 2015002442 A CL2015002442 A CL 2015002442A CL 2015002442 A CL2015002442 A CL 2015002442A CL 2015002442 A1 CL2015002442 A1 CL 2015002442A1
Authority
CL
Chile
Prior art keywords
treatment
thymphylosthetic
pi3kd
disorders related
pyrazolopyrimidine derivatives
Prior art date
Application number
CL2015002442A
Other languages
English (en)
Spanish (es)
Inventor
Wenqing Yao
Yun-Long Li
Wenyu Zhu
Song Mei
Joseph Glenn
Andrew P Combs
Eddy W Yue
Jr Thomas P Maduskuie
Richard B Sparks
Brent Douty
Chunhong He
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CL2015002442A1 publication Critical patent/CL2015002442A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2015002442A 2013-03-01 2015-08-31 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd CL2015002442A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361771480P 2013-03-01 2013-03-01

Publications (1)

Publication Number Publication Date
CL2015002442A1 true CL2015002442A1 (es) 2016-02-05

Family

ID=50288319

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002442A CL2015002442A1 (es) 2013-03-01 2015-08-31 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd

Country Status (32)

Country Link
US (6) US9932341B2 (OSRAM)
EP (3) EP4233869A3 (OSRAM)
JP (5) JP6545106B2 (OSRAM)
KR (5) KR102586858B1 (OSRAM)
CN (2) CN109010343A (OSRAM)
AR (1) AR094964A1 (OSRAM)
AU (5) AU2014223257B2 (OSRAM)
BR (1) BR112015020941A2 (OSRAM)
CA (1) CA2901993C (OSRAM)
CL (1) CL2015002442A1 (OSRAM)
CR (1) CR20150472A (OSRAM)
CY (1) CY1122712T1 (OSRAM)
DK (1) DK2961410T3 (OSRAM)
EA (2) EA202192151A1 (OSRAM)
ES (2) ES2945212T3 (OSRAM)
HR (1) HRP20200263T1 (OSRAM)
HU (1) HUE047719T2 (OSRAM)
IL (6) IL301180A (OSRAM)
LT (1) LT2961410T (OSRAM)
MX (2) MX367713B (OSRAM)
MY (1) MY177875A (OSRAM)
PE (1) PE20151996A1 (OSRAM)
PH (3) PH12021552233A1 (OSRAM)
PL (1) PL2961410T3 (OSRAM)
PT (1) PT2961410T (OSRAM)
RS (1) RS59958B1 (OSRAM)
SG (3) SG10201912275YA (OSRAM)
SI (1) SI2961410T1 (OSRAM)
SM (1) SMT202000043T1 (OSRAM)
TW (5) TWI687220B (OSRAM)
UA (1) UA119641C2 (OSRAM)
WO (1) WO2014134426A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US12173006B2 (en) 2018-09-05 2024-12-24 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
SI3513793T1 (sl) 2011-09-02 2021-07-30 Incyte Holdings Corporation Heterociklilamini kot zaviralci PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
HRP20201887T1 (hr) 2014-04-08 2021-02-05 Incyte Corporation LIJEČENJE B-STANIČNIH MALIGNITETA S KOMBINACIJOM INHIBITORA JAK i PI3K
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
MA41607B1 (fr) * 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
EP3792256B1 (en) 2016-01-05 2024-10-23 Incyte Corporation Pyridine compounds as pi3k-gamma inhibitors
EP3436434B1 (en) 2016-03-31 2020-07-08 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為PI3K-γ抑制劑之雜環化合物
TWI817956B (zh) * 2017-09-08 2023-10-11 英屬開曼群島商百濟神州有限公司 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
TWI839788B (zh) * 2018-01-10 2024-04-21 瑞士商愛杜西亞製藥有限公司 C5a受體調節劑
WO2019226213A2 (en) 2018-03-08 2019-11-28 Incyte Corporation AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
BR112020024427A2 (pt) * 2018-06-01 2021-03-23 Incyte Corporation regime de dosagem para o tratamento de distúrbios relacionados a pi3k
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN110833552A (zh) * 2018-08-15 2020-02-25 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途
WO2022115762A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
CN112808550B (zh) * 2020-12-28 2021-10-01 青岛理工大学 用于海洋工程的劣化免疫仿生防护界面及制备方法
WO2023114369A2 (en) 2021-12-16 2023-06-22 Incyte Corporation Topical formulations of pi3k-delta inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ES2225624T3 (es) 2000-06-28 2005-03-16 Smithkline Beecham Plc Procedimiento de molienda por via humeda.
ATE420879T1 (de) 2001-09-19 2009-01-15 Aventis Pharma Sa Indolizine als kinaseproteinhemmer
US7973031B2 (en) 2001-10-30 2011-07-05 Novartis Ag Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
BRPI0511978A (pt) 2004-06-10 2008-01-22 Irm Llc compostos e composições como inibidores de proteìnas quinases
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ
CN102532134A (zh) 2006-01-17 2012-07-04 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
WO2009157880A1 (en) 2008-06-27 2009-12-30 S*Bio Pte Ltd Pyrazine substituted purines
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
CA2738429C (en) * 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010118250A2 (en) 2009-04-09 2010-10-14 Oncothyreon, Incorporated Methods and compositions of pi-3 kinase inhibitors for treating fibrosis
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
PL2470546T3 (pl) 2009-08-28 2013-12-31 Takeda Pharmaceuticals Co Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン
US9249087B2 (en) 2011-02-01 2016-02-02 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
SI3513793T1 (sl) 2011-09-02 2021-07-30 Incyte Holdings Corporation Heterociklilamini kot zaviralci PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2015191677A1 (en) * 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MA41607B1 (fr) * 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
BR112020024427A2 (pt) 2018-06-01 2021-03-23 Incyte Corporation regime de dosagem para o tratamento de distúrbios relacionados a pi3k
WO2020102150A1 (en) * 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US12173006B2 (en) 2018-09-05 2024-12-24 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor

Also Published As

Publication number Publication date
PH12019501321B1 (en) 2020-10-12
CN109010343A (zh) 2018-12-18
AU2014223257B2 (en) 2018-11-29
SG10201912275YA (en) 2020-04-29
US20250289823A1 (en) 2025-09-18
PH12021552233A1 (en) 2022-07-18
EP2961410A1 (en) 2016-01-06
US9932341B2 (en) 2018-04-03
TWI841376B (zh) 2024-05-01
HK1221398A1 (en) 2017-06-02
TW202333734A (zh) 2023-09-01
MX367713B (es) 2019-09-03
KR102586858B1 (ko) 2023-10-11
CA2901993C (en) 2023-03-07
JP2023036609A (ja) 2023-03-14
US20220106318A1 (en) 2022-04-07
KR20150135327A (ko) 2015-12-02
SI2961410T1 (sl) 2020-03-31
RS59958B1 (sr) 2020-03-31
SMT202000043T1 (it) 2020-03-13
JP2019142941A (ja) 2019-08-29
US20220119393A1 (en) 2022-04-21
UA119641C2 (uk) 2019-07-25
CN105120871A (zh) 2015-12-02
AU2018264053A1 (en) 2018-12-06
AR094964A1 (es) 2015-09-09
MY177875A (en) 2020-09-24
JP7556010B2 (ja) 2024-09-25
IL283943B2 (en) 2023-08-01
IL274771A (en) 2020-07-30
KR20210110409A (ko) 2021-09-07
KR20220143146A (ko) 2022-10-24
MX2019010422A (es) 2019-10-15
AU2022218495B2 (en) 2024-10-03
AU2022218495A1 (en) 2022-09-08
PT2961410T (pt) 2020-03-02
PH12015501920B1 (en) 2016-01-18
ES2774436T3 (es) 2020-07-21
IL311666A (en) 2024-05-01
JP6545106B2 (ja) 2019-07-17
IL240784A0 (en) 2015-10-29
JP2021020914A (ja) 2021-02-18
JP7189185B2 (ja) 2022-12-13
CN105120871B (zh) 2018-08-10
CR20150472A (es) 2016-01-04
TWI736135B (zh) 2021-08-11
PE20151996A1 (es) 2016-01-13
MX2015011273A (es) 2015-12-03
TW202214254A (zh) 2022-04-16
TW202019428A (zh) 2020-06-01
DK2961410T3 (da) 2020-02-17
HUE047719T2 (hu) 2020-05-28
IL240784B (en) 2020-06-30
PH12015501920A1 (en) 2016-01-18
IL283943B1 (en) 2023-04-01
PL2961410T3 (pl) 2020-05-18
SG11201506654UA (en) 2015-09-29
HRP20200263T1 (hr) 2020-05-29
TW201929860A (zh) 2019-08-01
AU2014223257A1 (en) 2015-09-24
TWI687220B (zh) 2020-03-11
US20210332059A1 (en) 2021-10-28
IL267853B (en) 2020-03-31
KR20230145517A (ko) 2023-10-17
PH12019501321A1 (en) 2020-10-12
US12152033B2 (en) 2024-11-26
EP3632442A1 (en) 2020-04-08
TWI657090B (zh) 2019-04-21
US20140249132A1 (en) 2014-09-04
KR102717616B1 (ko) 2024-10-16
AU2020210278A1 (en) 2020-08-20
AU2020210278B2 (en) 2022-05-26
KR20240152422A (ko) 2024-10-21
IL267853A (en) 2019-09-26
EP4233869A3 (en) 2023-11-01
EA201591612A1 (ru) 2016-05-31
IL301180A (en) 2023-05-01
JP2025003975A (ja) 2025-01-14
KR102298150B1 (ko) 2021-09-07
JP2016510035A (ja) 2016-04-04
LT2961410T (lt) 2020-02-10
SG10201707130UA (en) 2017-10-30
IL283943A (en) 2021-07-29
AU2024287194A1 (en) 2025-01-23
ES2945212T3 (es) 2023-06-29
TW201444846A (zh) 2014-12-01
CA2901993A1 (en) 2014-09-04
JP6776399B2 (ja) 2020-10-28
EP3632442B1 (en) 2023-04-05
AU2018264053B2 (en) 2020-08-20
EP4233869A2 (en) 2023-08-30
BR112015020941A2 (pt) 2017-07-18
US20190040067A1 (en) 2019-02-07
KR102454308B1 (ko) 2022-10-14
EP2961410B1 (en) 2019-12-11
WO2014134426A1 (en) 2014-09-04
CY1122712T1 (el) 2021-03-12
EA202192151A1 (ru) 2021-12-31

Similar Documents

Publication Publication Date Title
CL2015002442A1 (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd
TWD187330S (zh) 汽車
TWD174059S (zh) 速克達摩托車
TWD163814S (zh) 車輛之頭燈
TWD166116S (zh) 車輛擋泥板
UY35500A (es) Indazoles sustituidos con heteroarilo
EP3061124A4 (en) Vertical non-planar semiconductor device for system-on-chip (soc) applications
TWD166111S (zh) 速克達摩托車
TWD171869S (zh) 速克達摩托車
PL2956347T3 (pl) Stolik pasażerski
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
EP3089845A4 (en) Five-axis machining apparatus
TWD180659S (zh) 車輛輪圈蓋(一)
TWD180660S (zh) 車輛輪圈蓋(二)
TWD160618S (zh) 硏磨件
PH12015502471A1 (en) Purine derivatives as cb2 receptor agonists
HRP20171882T1 (hr) Elektrolitna smjesa za elektrokemijske članke
EP3070716A4 (en) Xy table device
IN2013MU01113A (OSRAM)
TWD176305S (zh) 長形構件固定用鎖片
TWD173570S (zh) 汽車用頭燈組
MX369174B (es) Proceso para la preparación de un compuesto.
IN2013MU03768A (OSRAM)
TWD173206S (zh) 汽車用前散熱板
CR20130484A (es) Método para perparar compuestos macrocíclicos inhibidores de serina proteasas de hepatitis c